FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153081819> ?p ?o ?g. }

• W2153081819 endingPage "1029" @default.
• W2153081819 startingPage "1029" @default.
• W2153081819 abstract "To determine whether teletherapy with 6-mV photons can reduce visual loss in patients with subfoveal choroidal neovascularization in age-related macular degeneration.A multicenter, single-masked, randomized controlled trial of 12 Gy of external beam radiation therapy delivered to the macula of an affected eye vs observation only.Three United Kingdom-based hospital units.Patients with age-related macular degeneration, aged 60 years and older, who had subfoveal choroidal neovascularization and a visual acuity of 20/200 (logMAR 1.0) or better.Two hundred three patients were randomly assigned to radiotherapy or observation. Treatment was undertaken at designated radiotherapy centers, and patients assigned to the treatment group received a total dosage of 12 Gy of 6-mV photons in 6 fractions. Follow-up was scheduled at 3, 6, 12, and 24 months. After excluding protocol violators, the data from 199 patients were analyzed.The primary outcome measure was mean loss of distance visual acuity in the study eye at 12 and 24 months. Other outcome variables analyzed were near visual acuity and contrast sensitivity. The proportions of patients losing 3 or more or 6 or more lines of distance and near acuity and 0.3 or more or 0.6 or more log units of contrast sensitivity at each follow-up were also analyzed.At all time points, mean distance visual acuity was better in the radiotherapy-treated group than in the control group, but the differences did not reach statistical significance. At 24 months, analysis of the proportions of patients with loss of 3 or more (moderate) (P =.08) or 6 or more (severe) (P =.29) lines of distance vision showed that fewer treated patients had severe losses, but there was no statistically significant difference between groups. For near visual acuity, although there was no evidence of treatment benefit at 12 and 24 months, a significant difference in favor of treatment was present at 6 months (P =.048). When analyzed by the proportions of patients losing 3 lines of contrast sensitivity, there was a significant difference in favor of treatment at 24 months (P =.02). No adverse retinal effects were observed during the study, but transient disturbance of the precorneal tear film was noted in treated patients.The results of the present trial do not support the routine clinical use of external beam radiation therapy in subjects with subfoveal choroidal neovascularization in age-related macular degeneration." @default.
• W2153081819 created "2016-06-24" @default.
• W2153081819 creator A5001187649 @default.
• W2153081819 creator A5009342974 @default.
• W2153081819 creator A5019521414 @default.
• W2153081819 creator A5023372410 @default.
• W2153081819 creator A5029056211 @default.
• W2153081819 creator A5049856139 @default.
• W2153081819 creator A5054282792 @default.
• W2153081819 creator A5056293873 @default.
• W2153081819 creator A5061443692 @default.
• W2153081819 creator A5071015343 @default.
• W2153081819 creator A5086964962 @default.
• W2153081819 date "2002-08-01" @default.
• W2153081819 modified "2023-09-25" @default.
• W2153081819 title "Visual Outcomes in the Subfoveal Radiotherapy Study" @default.
• W2153081819 cites W1563630578 @default.
• W2153081819 cites W1601975653 @default.
• W2153081819 cites W1684796264 @default.
• W2153081819 cites W1984941380 @default.
• W2153081819 cites W1987805711 @default.
• W2153081819 cites W1993182821 @default.
• W2153081819 cites W1994752674 @default.
• W2153081819 cites W1996606921 @default.
• W2153081819 cites W2009917131 @default.
• W2153081819 cites W2017443285 @default.
• W2153081819 cites W2017766892 @default.
• W2153081819 cites W2024695401 @default.
• W2153081819 cites W2028672340 @default.
• W2153081819 cites W2028971484 @default.
• W2153081819 cites W2036924784 @default.
• W2153081819 cites W2062908169 @default.
• W2153081819 cites W2073644088 @default.
• W2153081819 cites W2082246284 @default.
• W2153081819 cites W2137678447 @default.
• W2153081819 cites W2157389251 @default.
• W2153081819 cites W2298592572 @default.
• W2153081819 cites W2300351767 @default.
• W2153081819 cites W2603205043 @default.
• W2153081819 doi "https://doi.org/10.1001/archopht.120.8.1029" @default.
• W2153081819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12149056" @default.
• W2153081819 hasPublicationYear "2002" @default.
• W2153081819 type Work @default.
• W2153081819 sameAs 2153081819 @default.
• W2153081819 citedByCount "80" @default.
• W2153081819 countsByYear W21530818192012 @default.
• W2153081819 countsByYear W21530818192013 @default.
• W2153081819 countsByYear W21530818192014 @default.
• W2153081819 countsByYear W21530818192015 @default.
• W2153081819 countsByYear W21530818192016 @default.
• W2153081819 countsByYear W21530818192018 @default.
• W2153081819 countsByYear W21530818192020 @default.
• W2153081819 countsByYear W21530818192023 @default.
• W2153081819 crossrefType "journal-article" @default.
• W2153081819 hasAuthorship W2153081819A5001187649 @default.
• W2153081819 hasAuthorship W2153081819A5009342974 @default.
• W2153081819 hasAuthorship W2153081819A5019521414 @default.
• W2153081819 hasAuthorship W2153081819A5023372410 @default.
• W2153081819 hasAuthorship W2153081819A5029056211 @default.
• W2153081819 hasAuthorship W2153081819A5049856139 @default.
• W2153081819 hasAuthorship W2153081819A5054282792 @default.
• W2153081819 hasAuthorship W2153081819A5056293873 @default.
• W2153081819 hasAuthorship W2153081819A5061443692 @default.
• W2153081819 hasAuthorship W2153081819A5071015343 @default.
• W2153081819 hasAuthorship W2153081819A5086964962 @default.
• W2153081819 hasConcept C118487528 @default.
• W2153081819 hasConcept C119767625 @default.
• W2153081819 hasConcept C141071460 @default.
• W2153081819 hasConcept C154945302 @default.
• W2153081819 hasConcept C15744967 @default.
• W2153081819 hasConcept C168563851 @default.
• W2153081819 hasConcept C169760540 @default.
• W2153081819 hasConcept C2776403814 @default.
• W2153081819 hasConcept C2776502983 @default.
• W2153081819 hasConcept C2776694393 @default.
• W2153081819 hasConcept C2777093970 @default.
• W2153081819 hasConcept C2778257484 @default.
• W2153081819 hasConcept C2781359195 @default.
• W2153081819 hasConcept C41008148 @default.
• W2153081819 hasConcept C509974204 @default.
• W2153081819 hasConcept C71924100 @default.
• W2153081819 hasConceptScore W2153081819C118487528 @default.
• W2153081819 hasConceptScore W2153081819C119767625 @default.
• W2153081819 hasConceptScore W2153081819C141071460 @default.
• W2153081819 hasConceptScore W2153081819C154945302 @default.
• W2153081819 hasConceptScore W2153081819C15744967 @default.
• W2153081819 hasConceptScore W2153081819C168563851 @default.
• W2153081819 hasConceptScore W2153081819C169760540 @default.
• W2153081819 hasConceptScore W2153081819C2776403814 @default.
• W2153081819 hasConceptScore W2153081819C2776502983 @default.
• W2153081819 hasConceptScore W2153081819C2776694393 @default.
• W2153081819 hasConceptScore W2153081819C2777093970 @default.
• W2153081819 hasConceptScore W2153081819C2778257484 @default.
• W2153081819 hasConceptScore W2153081819C2781359195 @default.
• W2153081819 hasConceptScore W2153081819C41008148 @default.
• W2153081819 hasConceptScore W2153081819C509974204 @default.
• W2153081819 hasConceptScore W2153081819C71924100 @default.
• W2153081819 hasIssue "8" @default.

• next